Effectiveness of meningococcal C conjugate vaccine in Salvador, Brazil: a case-control study

PLoS One. 2015 Apr 13;10(4):e0123734. doi: 10.1371/journal.pone.0123734. eCollection 2015.

Abstract

Background: During a citywide epidemic of serogroup C meningococcal disease in Salvador in 2010, Brazil, the state government initiated mass vaccination targeting two age groups with high attack rates: individuals aged <5 years and 10-24 years. More than 600,000 doses of meningococcal serogroup C conjugate vaccines were administered. We performed a case-control study to evaluate vaccine uptake, document vaccine effectiveness and identify reasons for non-vaccination.

Methods and findings: Population-based surveillance identified patients with laboratory-confirmed invasive meningococcal C (MenC) disease during 2010. Information on MenC vaccination was obtained from case patients and age-matched individuals from the same neighborhoods. MenC vaccine effectiveness was estimated based on the exact odds ratios obtained by conditional logistic regression analysis. Of 51 laboratory-confirmed cases of serogroup C meningococcal disease among patients <5 and 10-24 years of age 50 were included in the study and matched with 240 controls. Overall case-fatality was 25%. MenC vaccine coverage among controls increased from 7.1% to 70.2% after initiation of the vaccination campaign. None of the 50 case patients but 70 (29.2%) of the 240 control individuals, including 59 (70.2%) of 84 matched with cases from the period after MenC vaccination, had received at least one MenC vaccine dose. Overall effectiveness of MenC was 98% with a lower 95% exact confidence limit of 89%.

Conclusions: MenC vaccines administered during the meningococcal epidemic were highly effective, suggesting that rapid vaccine uptake through campaigns contributed to control of meningococcal disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Brazil
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunization Programs / statistics & numerical data*
  • Immunization Schedule
  • Infant
  • Male
  • Meningococcal Infections / prevention & control*
  • Meningococcal Vaccines / therapeutic use*
  • Neisseria meningitidis
  • Neisseria meningitidis, Serogroup C
  • Young Adult

Substances

  • Meningococcal Vaccines
  • serogroup C meningococcal conjugate vaccine

Grants and funding

This work was supported by the grants from the Bahia State Foundation (PP-SUS0001/2009) and Secretary of Health Surveillance (SVS/MS - 284/2013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.